-
Impact of holoprosencephaly, exomphalos, megacystis and increased nuchal translucency on first-trimester screening for chromosomal abnormalities.
Syngelaki A, Guerra L, Ceccacci I, Efeturk T, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:45-48. pdf -
Maternal age and adverse pregnancy outcomes: a cohort study.
Khalil A, Syngelaki A, Maiz N, Zinevich Y, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:634-43. pdf -
Maternal serum retinol-binding protein-4 at 11-13weeks' gestation in normal and pathological pregnancies.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH.
Metabolism 2013;62:814-9. -
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705. -
Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks.
Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH.
Prenat Diagn 2011;31:135-41. -
The 11-13-week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis.
Kagan KO, Staboulidou I, Syngelaki A, Cruz JJ, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;36:10-4. -
The 11-14 week scan.
Nicolaides KH, Heath V, Liao AW.
Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:581-94. -
Screening for fetal abnormalities in multiple pregnancies.
Sebire NJ, Nicolaides KH.
Baillieres Clin Obstet Gynaecol 1998;12:19-36.